IntelliCyt is an Albuquerque, NM-based provider of integrated platforms to accelerate drug discovery, antibody discovery and immunology. It develops a platform featuring software-assisted automation, analysis, and experiment-level visualization tools for the study of cells, enhancing suspension-cell screening workflows from sample preparation through results. The system enables rapid, multiplexed analysis of cells and beads in suspension in 96, 384, and 1536 well plates. Its proprietary sample delivery system allows miniaturization of assays to conserve precious sample and reduce reagent use per well. Led by R. Terry Dunlay, President and CEO, the company recently closed a $7.4M financing comprised of $5.4M in venture capital and a $2M debt facility. The VC round included participation from current investors and the debt facility expands its capital resources. IntelliCyt develops high-throughput, high-content cell- and bead-based screening solutions used in phenotypic drug discovery, antibody discovery and in vitro toxicity testing. Its flagship product, the iQue® Screener, combines flow cytometry detection with sample processing to run a 96‑well microplate in about three minutes. The iQue Screener is offered as part of a complete solution of application-specific reagent kits and software products with applications in pharmaceutical, biotechnology, and life science research. The company is headquartered in Albuquerque, NM and was founded in 2006; it is led by Founder, President and CEO R. Terry Dunlay. IntelliCyt recently secured debt financing to support ongoing operations. The company intends to use the funds for working capital and to support product development and marketing initiatives. IntelliCyt develops high-throughput, high-content cell- and bead-based assay screening solutions used in phenotypic drug discovery, antibody discovery and in vitro toxicity testing. Its product lineup includes reagent kits for these applications. The company completed an $8M financing round led by Arboretum Ventures with participation from Prolog Ventures, Verge Fund and New Mexico Community Capital. IntelliCyt intends to use the proceeds to expand commercial efforts globally, grow manufacturing capacity and expand its suite of reagent kits. Arboretum partners Tim Petersen and George Dunbar will join the board following the financing. Founded in 2006 and based in Albuquerque, New Mexico, the company is led by President and CEO R. Terry Dunlay.

Total raised

$19M

Funding rounds

5

Latest round

Equity

Latest activity

Oct 2015